Please login to the form below

Not currently logged in
Email:
Password:

farletuzumab

This page shows the latest farletuzumab news and features for those working in and with pharma, biotech and healthcare.

Late-stage ovarian cancer

Late-stage ovarian cancer

Menarini Biotech's abagovomab and Morphotek/ Eisai's farletuzumab have both had disappointing results in late-stage clinical trials. ... Farletuzumab had also entered global phase III trials, in combination with carboplatin and a taxane, in patients with

Latest news

  • Eisai's farletuzumab fails ovarian cancer trial Eisai's farletuzumab fails ovarian cancer trial

    Eisai's farletuzumab fails ovarian cancer trial. Unable to improve progression-free survival. ... Morphotek remains committed to research to understand the potential role of farletuzumab in ovarian and other types of cancer.".

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Eisai: Bucking the trend with R&D growth Eisai: Bucking the trend with R&D growth

    The monoclonal antibody farletuzumab is in phase III trials for ovarian cancer, and has reached the phase II stage for non-small cell lung cancer, while lenvatinib is also in phase

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics